File Download
 
 
Supplementary

Conference Paper: A phase I/II study of Foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC)
  • Basic View
  • Metadata View
  • XML View
TitleA phase I/II study of Foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC)
 
AuthorsYau, TCC
Sukeepaisarnjaroen, W
Chao, Y
Yen, CJ
Lausoontornsiri, W
Chen, PJ
Sanpajit, T
Lencioni, R
Camp, A
Kallender, H
Ottesen, LH
Poon, RTP
 
Issue Date2011
 
CitationJournal of Clinical Oncology, v. 29 n. Suppl, p. abstr 4082 [How to Cite?]
 
DC FieldValue
dc.contributor.authorYau, TCC
 
dc.contributor.authorSukeepaisarnjaroen, W
 
dc.contributor.authorChao, Y
 
dc.contributor.authorYen, CJ
 
dc.contributor.authorLausoontornsiri, W
 
dc.contributor.authorChen, PJ
 
dc.contributor.authorSanpajit, T
 
dc.contributor.authorLencioni, R
 
dc.contributor.authorCamp, A
 
dc.contributor.authorKallender, H
 
dc.contributor.authorOttesen, LH
 
dc.contributor.authorPoon, RTP
 
dc.date.accessioned2012-08-16T06:11:05Z
 
dc.date.available2012-08-16T06:11:05Z
 
dc.date.issued2011
 
dc.identifier.citationJournal of Clinical Oncology, v. 29 n. Suppl, p. abstr 4082 [How to Cite?]
 
dc.identifier.epageabstr 4082
 
dc.identifier.hkuros202728
 
dc.identifier.issueSuppl
 
dc.identifier.spageabstr 4082
 
dc.identifier.urihttp://hdl.handle.net/10722/160425
 
dc.identifier.volume29
 
dc.languageeng
 
dc.relation.ispartofJournal of Clinical Oncology
 
dc.titleA phase I/II study of Foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC)
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Yau, TCC</contributor.author>
<contributor.author>Sukeepaisarnjaroen, W</contributor.author>
<contributor.author>Chao, Y</contributor.author>
<contributor.author>Yen, CJ</contributor.author>
<contributor.author>Lausoontornsiri, W</contributor.author>
<contributor.author>Chen, PJ</contributor.author>
<contributor.author>Sanpajit, T</contributor.author>
<contributor.author>Lencioni, R</contributor.author>
<contributor.author>Camp, A</contributor.author>
<contributor.author>Kallender, H</contributor.author>
<contributor.author>Ottesen, LH</contributor.author>
<contributor.author>Poon, RTP</contributor.author>
<date.accessioned>2012-08-16T06:11:05Z</date.accessioned>
<date.available>2012-08-16T06:11:05Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>Journal of Clinical Oncology, v. 29 n. Suppl, p. abstr 4082</identifier.citation>
<identifier.uri>http://hdl.handle.net/10722/160425</identifier.uri>
<language>eng</language>
<relation.ispartof>Journal of Clinical Oncology</relation.ispartof>
<title>A phase I/II study of Foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC)</title>
<type>Conference_Paper</type>
<identifier.hkuros>202728</identifier.hkuros>
<identifier.volume>29</identifier.volume>
<identifier.issue>Suppl</identifier.issue>
<identifier.spage>abstr 4082</identifier.spage>
<identifier.epage>abstr 4082</identifier.epage>
</item>